# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...
B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...
The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...
UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.
HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...
All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to ...
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...